Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
Author(s) -
Balachandran Kumarendran,
Michael OʼReilly,
Anuradhaa Subramanian,
Dana Šumilo,
Konstantinos A. Toulis,
Krishna Gokhale,
Chandrika Neelakanthi Wijeratne,
Arri Coomarasamy,
Abd A. Tahrani,
Laurent Azoulay,
Wiebke Arlt,
Krishnarajah Nirantharakumar
Publication year - 2021
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc21-0437
Subject(s) - medicine , polycystic ovary , hazard ratio , population , nested case control study , odds ratio , obstetrics , retrospective cohort study , type 2 diabetes , cohort study , gynecology , diabetes mellitus , endocrinology , confidence interval , insulin resistance , environmental health
Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom